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Alzheimer’s disease biomarkers are becoming increasingly important for characterizing the longitudinal course of
disease, predicting the timing of clinical and cognitive symptoms, and for recruitment and treatment monitoring
in clinical trials. In this work, we develop and evaluate three methods for modelling the longitudinal course of amyloid accumulation in three cohorts using amyloid PET imaging. We then use these novel approaches to investigate factors that inﬂuence the timing of amyloid onset and the timing from amyloid onset to impairment onset in the
Alzheimer’s disease continuum.
Data were acquired from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Baltimore Longitudinal Study
of Aging (BLSA) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP). Amyloid PET was used to assess global amyloid burden. Three methods were evaluated for modelling amyloid accumulation using 10-fold cross-validation and holdout validation where applicable. Estimated amyloid onset age was compared across all three
modelling methods and cohorts. Cox regression and accelerated failure time models were used to investigate
whether sex, apolipoprotein E genotype and e4 carriage were associated with amyloid onset age in all cohorts. Cox
regression was used to investigate whether apolipoprotein E (e4 carriage and e3e3, e3e4, e4e4 genotypes), sex or age
of amyloid onset were associated with the time from amyloid onset to impairment onset (global clinical dementia
rating ≥1) in a subset of 595 ADNI participants that were not impaired before amyloid onset.
Model prediction and estimated amyloid onset age were similar across all three amyloid modelling methods. Sex and
apolipoprotein E e4 carriage were not associated with PET-measured amyloid accumulation rates. Apolipoprotein E
genotype and e4 carriage, but not sex, were associated with amyloid onset age such that e4 carriers became amyloid
positive at an earlier age compared to non-carriers, and greater e4 dosage was associated with an earlier amyloid onset age. In the ADNI, e4 carriage, being female and a later amyloid onset age were all associated with a shorter time
from amyloid onset to impairment onset. The risk of impairment onset due to age of amyloid onset was non-linear
and accelerated for amyloid onset age >65. These ﬁndings demonstrate the feasibility of modelling longitudinal amyloid accumulation to enable individualized estimates of amyloid onset age from amyloid PET imaging. These estimates provide a more direct way to investigate the role of amyloid and other factors that inﬂuence the timing of
clinical impairment in Alzheimer’s disease.
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Introduction
Alzheimer’s disease is characterized by the aggregation of
beta-amyloid plaques and neuroﬁbrillary tau tangles, followed by
subsequent neurodegeneration and progressive cognitive decline.1–4
The disease course consists of an extended ‘preclinical’ phase in
which Alzheimer’s disease pathology is accumulating before the onset of clinical symptoms.5 The preclinical phase may last 20 years or
more, although the empirical basis for this is largely at the group level6–9 where studies have observed predictable change in amyloid levels.7,9–11 Robust methods for estimating amyloid onset and thereby
demarcating the onset of preclinical Alzheimer’s disease in individuals are needed and appear to be feasible.11–15 Although conceptually promising, existing methods require further validation in
additional cohorts to elucidate Alzheimer’s disease timing and dementia risk. Additionally, autonomous methods could broaden accessibility to other cohorts and applications such as spatiotemporal
modelling. Here, we report two new autonomous methods for estimating individualized amyloid onset age and evaluate these methods
with our previously published approach.13 We then use these methods to investigate factors that inﬂuence amyloid onset age, amyloid
accumulation rates and time from amyloid onset to impairment.
Apolipoprotein E (APOE) genotype, speciﬁcally APOE-e4 allele
carriage and gene dosage, is the most established risk factor for
beta-amyloid accumulation and cognitive impairment in sporadic
Alzheimer’s disease.16 Dementia prevalence studies demonstrate
a gene–dose-dependent relationship wherein dementia risk increases and dementia onset age decreases with lower APOE-e2 dosage and higher e4 dosage.17–19 Some studies have observed an
interaction between APOE and sex such that females with one or
more APOE-e4 alleles experience earlier dementia onset relative
to e4 non-carriers, but a similar result was not observed for male
APOE-e4 carriers.20 Biomarker studies indicate amyloid positivity

(A+) prevalence increases with increasing APOE-e4 dosage, and decreases with increasing e2 gene dosage (except e2e4 carriers) compared to e3 homozygotes.8,21 Neuroimaging studies have also
shown e4 carriers become A+ earlier than non-carriers.8,12,22,23
Thus, an explanation for e4 carriers becoming impaired earlier in
life is that they start accumulating beta-amyloid earlier in life. To
test this hypothesis, we need to determine whether the relationship between APOE genotype and A+ prevalence is due to an earlier
amyloid onset age, a difference in amyloid accumulation rates or a
combination of both. There is also a need to determine whether factors such as APOE genotype, sex or age of amyloid onset shorten/
lengthen the preclinical timeframe.
This work builds on two previous papers where we demonstrated
methods that provide individualized estimated A+ onset age (EAOA)
based on one or more

11

C-Pittsburgh Compound B (PiB) PET scans.

These methods were developed separately in the Baltimore
Longitudinal Study on Aging (BLSA)12 and the Wisconsin Registry
for Alzheimer’s Prevention (WRAP).13 The BLSA study used nonlinear mixed-effects modelling with random effects to derive EAOA
and showed asymptomatic APOE-e4 carriers exhibited earlier EAOA
than non-carriers. The WRAP study used group-based trajectory
modelling (GBTM) and Bayes’ theorem to obtain EAOA and showed
EAOA could align observations by A+ duration (age at observation
minus EAOA; termed amyloid chronicity). Higher amyloid chronicity
was associated with faster rates of cognitive decline, increased cognitive impairment risk and was more strongly associated with
MK-6240 tau PET than age in initially unimpaired WRAP participants.
In this work, we present a simpliﬁcation to the GBTM approach
and introduce two new autonomous methods for modelling longitudinal amyloid PET trajectories. All algorithms were evaluated in
three cohorts: the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) using 18F-ﬂorbetapir, the BLSA using 11C-PiB and the WRAP
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Amyloid onset, APOE, sex and impairment
using 11C-PiB. Our aims were to: (i) cross-validate three methods to
model amyloid accumulation, impute EAOA and predict amyloid
PET levels; (ii) characterize associations between APOE genotype
and sex with EAOA and amyloid accumulation rates; and (iii) characterize dementia risk and time from EAOA to dementia associated
with APOE genotype, EAOA and sex.

Materials and methods
Study participants

Cohort descriptions
ADNI
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and lowest binding estimate variance (see Supplementary material
for details).33–37 ADNI cortical Florbetapir standard uptake value ratios (SUVRs; eroded white matter reference region) processed by
the Banner Alzheimer’s Institute were downloaded from the 22
November, 2019 data freeze. Mean cortical PiB distribution volume
ratios (DVRs; cerebellar grey matter reference region) were estimated
using different reference tissue methods for BLSA37 (DVRRTM3P) and
WRAP (DVRLGA).36 A+ thresholds were established based on separate
studies for each cohort. Florbetapir SUVRWM > 0.8 (33.1 Centiloids)
was used for ADNI based on receiver operating characteristic analyses (AUC 0.91, 91% negative agreement, 82% positive agreement)
comparing SUVRWM with a published threshold from Berkeley processed data.38 BLSA used DVRRTM3P > 1.066 (20.6 Centiloids) derived
from Gaussian mixture modelling.12 DVRLGA > 1.19 (21.6 Centiloids)
was used for WRAP based on receiver operating characteristic analysis with visual assessment.39 DVR and SUVRWM values were
mapped to Centiloids40 using linear regression for reporting and
to estimate the time difference between A+ thresholds
(Supplementary material).

Amyloid trajectory modelling and estimated
amyloid onset age

Data used in this article were obtained from the ADNI database (adni.loni.usc.edu). ADNI was launched in 2003 as a public–private
partnership, led by Principal Investigator Michael W. Weiner, MD.
The primary goal of ADNI has been to test whether serial MRI,
PET, other biological markers, and clinical and neuropsychological
assessment can be combined to measure the progression of mild
cognitive impairment (MCI) and early Alzheimer’s disease. For
up-to-date information, see www.adni-info.org. Diagnostic cognitive status was established from the ADNI diagnosis table.

Three methods were used to model longitudinal amyloid PET trajectories and estimate amyloid onset age (EAOA). Descriptions of
each method are provided next with additional details in the supplement. Models were trained separately for each cohort using subsets of participants with ≥2 amyloid PET scans (Table 1, left three
columns). EAOA and A+ duration (A+ duration = age at observation—EAOA) were estimated from trained models for all
participants.

BLSA

Group-based trajectory modelling

At enrolment into the BLSA PET neuroimaging substudy,27 participants were free of CNS disease, severe cardiac disease, severe pulmonary disease and metastatic cancer. Participants with a clinical
dementia rating (CDR)28 of zero and ≤3 errors on the Blessed
Information-Memory-Concentration test29 were categorized as
cognitively normal; otherwise, cognitive status was determined
by consensus case conference on review of clinical and neuropsychological data. Dementia and MCI diagnoses were based on
Diagnostic and Statistical Manual of Mental Disorders30 (DSM-IIIR)
and Petersen criteria,31 respectively.

As previously reported,13 the GBTM EAOA method applies
GBTM41,42 to identify the optimal number and shape of age-related
DVR/SUVR group trajectory equations (up to cubic polynomial).
EAOA is calculated for each group function by solving for age at
the A+ threshold. Life expectancy at the last scan is used13 to
estimate EAOA for an intercept-only (representing amyloid
non-accumulators) group function. Each participant’s EAOA is
calculated as the weighted sum of group function EAOAs
with weights derived from residuals for each function
(Supplementary material). DVR/SUVR prediction is accomplished by modelling the DVR/SUVR versus A+ duration curve
using piecewise regression, and solving this modelled curve for
DVR/SUVR at the time difference between the reference scan
and the scan of interest for prediction.

WRAP
WRAP participants are unimpaired at enrolment and complete
comprehensive neuropsychological assessments roughly biennially.24 Cognitive status (unimpaired, MCI, dementia) was established
by consensus conference as previously reported for WRAP
participants.32
Diagnostic status (unimpaired, MCI, dementia) was established
across cohorts for descriptive purposes using similar criteria.
Clinical progression was assessed using the CDR scale when
applicable.28

Amyloid PET processing, quantiﬁcation
and positivity
Cortical amyloid burden was assessed using either dynamic 11C-PiB
(BLSA and WRAP) or late-frame 18F-ﬂorbetapir (ADNI) PET imaging
using separate processing and quantiﬁcation methods optimized
within each cohort to provide the highest quantitative accuracy

Ordinary differential equation–Gaussian process
The ordinary differential equation–Gaussian process (ODE–GP)
algorithm is a gradient matching method43 that ﬁts a nonparametric ODE to data. The ﬁrst step of ODE–GP estimates
DVR/SUVR gradients for each participant using linear regression. The second step solves a non-standard GP regression
problem using data from all participants in the sample, accounting for both the noise in measurements and in the estimated gradients. An approximate solution is provided using a
second-order Taylor expansion of the Gaussian process using
a Gaussian kernel. The kernel radius is estimated by maximizing the marginal likelihood of the data. The ﬁtted model allows
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Participants were included from ADNI, BLSA and WRAP studies if
they had at least one amyloid PET scan and a cognitive diagnosis
available in addition to each cohort’s inclusion/exclusion criteria
(see Johnson et al.24 Ferruci,25 Weiner et al.26 and Resnick
et al.27 references for cohort information; participant summary in
Table 1). Participants’ written consent was obtained in each source
study according to the Declaration of Helsinki and under local
Institutional Review Board approvals.
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Table 1 Demographics and cohort summaries
Modelling sets
a

ADNI

All participants
a

BLSA

WRAP

ADNI

BLSA

WRAP

739
345 (46.7)

142
71 (50.0)

179
120 (67.0)

1215
570 (46.9)

207
104 (50.2)

272
185 (68.0)

2 (0.3)
11 (1.5)
1 (0.1)
24 (3.2)
689 (93.2)
11 (1.5)
1 (0.1)

0
2 (1.4)
2 (1.4)
25 (17.6)
112 (78.9)
1 (0.7)
0 ()

1 (0.6)
1 (0.6)
0
7 (3.9)
169 (94.4)
1 (0.6)
0

2 (0.2)
19 (1.6)
2 (0.2)
46 (3.8)
1127 (92.8)
16 (1.3)
3 (0.2)

0
4 (1.9)
3 (1.4)
36 (17.4)
162 (78.3)
2 (1.0)
0

4 (1.5)
1 (0.4)
0
10 (3.7)
256 (94.1)
1 (0.4)
0

1 (0.1)
67 (9.1)
15 (2.0)
371 (50.2)
233 (31.5)
52 (7.0)
0

1 (0.7)
15 (10.6)
6 (4.2)
84 (59.2)
33 (23.2)
2 (1.4)
1 (0.7)

0
16 (8.9)
5 (2.8)
88 (49.2)
63 (35.2)
7 (3.9)
0

2 (0.2)
99 (8.1)
24 (2.0)
589 (48.5)
394 (32.4)
107 (8.8)
0

2 (1.0)
25 (12.1)
8 (3.9)
118 (57.0)
49 (23.7)
3 (1.4)
2 (1.0)

0
30 (11.0)
10 (3.7)
132 (48.5)
88 (32.4)
10 (3.7)
2 (0.7)

303 (41.0)
386 (52.2)
50 (6.8)
73.4 (7.4)
4.14 (1.93)

142 (100)
0
0
75.9 (7.9)
5.13 (3.18)

177 (98.9)
2 (1.1)
0
61.0 (6.2)
6.25 (2.11)

461 (37.9)
559 (46.0)
195 (16.0)
73.7 (7.6)
2.52 (2.52)

207 (100)
0
0
75.8 (8.2)
3.52 (3.6)

261 (96.0)
9 (3.3)
2 (0.7)
62.4 (6.7)
4.11 (3.43)

—
307 (41.5)
235 (31.8)
163 (22.1)
33 (4.5)
1 (0.1)
0
0
0
0
0

—
39 (18.8)
38 (18.4)
25 (12.1)
14 (6.8)
13 (6.3)
3 (1.4)
5 (2.4)
3 (1.4)
1 (0.5)
1 (0.5)

—
56 (20.6)
96 (35.3)
25 (9.2)
2 (0.7)
0
0
0
0
0
0

476 (39.2)
307 (25.3)
235 (19.3)
163 (13.4)
33 (2.7)
1 (0.1)
0
0
0
0
0

65 (31.4)
39 (18.8)
38 (18.4)
25 (12.1)
14 (6.8)
13 (6.3)
3 (1.4)
5 (2.4)
3 (1.4)
1 (0.5)
1 (0.5)

93 (34.2)
56 (20.6)
96 (35.3)
25 (9.2)
2 (0.7)
0
0
0
0
0
0

SD = standard deviation.
a

Subsets from each cohort with two or more amyloid PET scans used for longitudinal modelling.

for prediction of past and future DVR/SUVR for a participant
using a single DVR/SUVR value at a given age as an initial condition for the ODE. A prediction is made by integrating numerically the ODE using the Euler method. Since the ﬁtted model is
autonomous (time-invariant), we summarize the ﬁtted data
with a growth curve deﬁning the DVR/SUVR as function of the
time since the A+ threshold.

Sampled iterative local approximation
The sampled iterative local approximation (SILA) algorithm uses
discrete sampling of DVR/SUVR versus age data to establish the relationship between DVR/SUVR rate and DVR/SUVR. Numerical
smoothing (robust LOESS) and Euler’s method are used to numerically integrate these data to generate a non-parametric DVR/SUVR
versus A+ duration curve with zero time corresponding to the A+
threshold. EAOA is calculated for each person by ﬁrst solving this
curve for time using a person’s observed DVR/SUVR, and subtracting the estimated A+ duration from their age at that scan. SUVR/
DVR is estimated for antecedent or prospective scans by solving

the DVR/SUVR versus time curve for DVR/SUVR at the time corresponding to the difference between reference and target scans.

Statistical analyses
Aim 1: evaluating and comparing amyloid modelling
methods
Aim 1 compared EAOA and A+ duration outcomes across the three
methods and evaluated the predictive performance of each method
within each cohort. The composition of the model training and testing sets varied depending on the analysis goals described next.
Computational speed was evaluated for autonomous methods
ODE–GP and SILA (Supplementary material).

Inter-method comparisons of EAOA and amyloid
accumulation curves
EAOA and SUVR/DVR versus A+ duration curves were compared
across methods in each cohort. EAOA and A+ duration were
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N
Female, n (%)
Race, n (%)
American Indian or Alaskan Native
Asian
Native Hawaiian or Other Paciﬁc Islander
Black or African American
White
Other or multiple
Unavailable/unknown
APOE genotype, n (%)
e2e2
e2e3
e2e4
e3e3
e3e4
e4e4
Unknown
Baseline diagnosis, n (%)
Unimpaired
MCI
Dementia
Baseline age, mean (SD)
PET follow-up duration years, mean (SD)
Number of amyloid PET scans, n (%)
1
2
3
4
5
6
7
8
9
10
11

a

Amyloid onset, APOE, sex and impairment
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e2e4), and separately by APOE genotype (e2e3, e2e4, e3e3, e3e4,
and e4e4), were compared in each dataset. Survival curves were
compared using log-rank tests with pairwise comparisons conducted for APOE groups. Median survival times with 95% conﬁdence intervals for APOE groups (e4 carriers and non-carriers;
APOE genotypes) were reported for groups that reached 50% probability of remaining A−. APOE-e2e2 carriers were excluded from
genotype analyses due to low frequency. We used Cox proportional hazards models to quantify A+ risk by APOE-e4 carriage, and by
APOE genotype in separate models. Accelerated failure time (AFT)
models quantiﬁed relative differences in EAOA by APOE-e4 carriage and genotype. Cox proportional hazards and the AFT models
covaried for sex.

Method predictive validity
Predictive validity to estimate future and past DVR/SUVR and elevated or non-elevated amyloid PET (A±) status was evaluated using
holdout validation (all methods; ADNI) and 10-fold cross-validation
(ODE–GP and SILA; all cohorts). Holdout validation was limited to
ADNI because the larger sample enabled separate training and testing partitions with similar amyloid distributions. GBTM was omitted from 10-fold cross-validation because it would have required
∼90 h of human time. Stratiﬁcation methods for 10-fold and holdout validation samples are provided in the Supplementary
Material. For each method and cohort, models were trained on subsets of longitudinal data, and then DVR/SUVR and age at a single
reference scan (last or ﬁrst) were used to predict DVR/SUVR at an
earlier or later PET scan for participants omitted from model training. Forwards prediction was evaluated by predicting DVR/SUVR at
each person’s last observation inputting each person’s ﬁrst observation, whereas backwards prediction used the last observation
to predict DVR/SUVR at the ﬁrst observation. DVR/SUVR prediction
residuals were used to investigate associations with factors that
might inﬂuence model prediction (reference DVR/SUVR, age and
time from reference scan) and to generate model summary statistics. A± prediction performance was evaluated using balanced accuracy (adjusted for imbalanced A+ and A− frequency), sensitivity
and speciﬁcity. We also compared EAOA estimates derived from insample versus out-of-sample prediction schemes graphically and
using Pearson correlations. After observing similar model performance for ODE–GP and SILA methods, analyses for aims 2 and 3 used
the average of ODE–GP and SILA EAOA.

Aim 2: APOE and sex associations with EAOA
and amyloid accumulation rate
The impact of sex and APOE-e4 carriage on amyloid accumulation
rates were evaluated by investigating the relationship between
DVR/SUVR rate and DVR/SUVR. Smoothed DVR/SUVR rate versus
DVR/SUVR curves were generated for each cohort, and separately
for comparison groups (APOE-e4 carriers versus non-carriers; males
versus females) by applying local regression with weighted linear
least squares to the mean within-person DVR/SUVR rate versus
DVR/SUVR data. Ninety-ﬁve percent conﬁdence intervals were estimated using 1000 bootstrapped samples with replacement.
The second part of Aim 2 addressed three questions: (i) what
age does A+ onset occur; (ii) what is the A+ risk conferred by
APOE; and (iii) does A+ onset differ between APOE groups? We assessed whether and how much EAOA differs across APOE genotypes using survival analyses, as previously described.44 The
event time was EAOA for A+ individuals and age at last PET observation (right censored) for individuals that were A− but could become A+. Kaplan–Meier plots by APOE-e4 carriage (excluding

Aim 3: Effects of APOE, sex and EAOA on time from
A+ onset to dementia
WRAP and BLSA observed few clinical conversions compared
to ADNI. Therefore, we used a subset of 595 ADNI participants
to investigate the effects of EAOA, sex and APOE on time from
EAOA to impairment. ADNI participants were included if they
were not impaired before EAOA, with CDR ≥1 as the criterion
for impairment. 28 APOE-e2e4 carriers were excluded due to
the combination of risk and protective effects and low frequency (n = 15). We used Cox survival models to estimate hazard and survival functions of impairment from EAOA and their
relationship with APOE-e4 carriage, sex and EAOA. The Cox
model outcome was time from EAOA to impairment for those
who became impaired, and time from EAOA to age at last
CDR (right censored) for those that remained unimpaired.
Predictors included education, sex, APOE-e4 carriage, EAOA,
EAOA 2 , sex*EAOA, sex*EAOA 2 , APOE*EAOA, APOE*EAOA 2 .
EAOA 2 was included to allow for accelerated log hazard of impairment with increasing EAOA. Non-signiﬁcant interactions
were removed from the model. Analyses were repeated using
APOE genotypes (e3e3, e3e4, e4e4) instead of APOE-e4 carriage.
Results are reported as hazard ratios, median unimpaired survival time and the ten-year unimpaired rate with conﬁdence
intervals estimated using 1000 bootstrapped samples with
replacement.

Data availability
Data from the WRAP (https://wrap.wisc.edu) and BLSA (https://blsa.
nih.gov) can be requested through an online submission process.
ADNI data can be obtained via the ADNI and LONI websites. ODE–
GP and SILA algorithms are available at https://gitlab.com/
bilgelm/amyloid-ode-gp
and
https://github.com/BetthauserNeuro-Lab/SILA-AD-Biomarker, respectively.

Results
Study sample descriptive statistics
and demographics
Table 1 shows demographic and summary statistics for the three
cohorts and model training subsets. ADNI and BLSA cohorts were
11.3 and 13.4 years older, respectively, than WRAP, which had a
mean age of 62.4 years at baseline amyloid PET scan. BLSA and
WRAP samples were primarily unimpaired at baseline PET whereas
ADNI had 62% impaired participants (MCI or dementia). Study participants primarily identiﬁed as white (ADNI: 93%, BLSA: 78%,
WRAP: 94%). Demographic variables were similar for the subsets
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estimated for all participants using each participant’s observed
DVR/SUVR and age at their last available amyloid PET scan.
Pearson correlations compared EAOA between methods separately
for A+ and A− groups. Amyloid accumulation curves (i.e. DVR/SUVR
versus estimated A+ duration) were compared by plotting observed
DVR/SUVR values at the ﬁrst scan as a function of estimated A+ duration referencing the last scan for participants with ≥2 scans. EAOA
accuracy was evaluated in A− to A+ converters (n = 72 ADNI; n = 6
BLSA; n = 22 WRAP) by calculating the proportion of times age last
A− ≤ EAOA ≤ age ﬁrst A+ and calculating the conversion midpoint
error (years between EAOA and the midpoint age between A− A+
observations).
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used for model training and testing. The mean (SD) PET follow-up
for these subsets was 4.14 (1.93), 5.13 (3.18) and 6.25 (2.11) years
for ADNI, BLSA and WRAP, respectively.

Aim 1: amyloid modelling methods comparison and
evaluation
Inter-method comparisons
Amyloid versus age data and A+ thresholds are shown for each cohort in Fig. 1 (top row). Each cohort had a visually apparent group of
amyloid non-accumulators below the A+ threshold and a group of

amyloid accumulators crossing and above the threshold. Overall,
the three methods produced similar amyloid accumulation patterns (middle row, Fig. 1), with the largest differences observed in
ADNI. EAOA was highly linearly correlated between method pairs
in A+ participants (rPearson = 0.88–1.00) with lower correlations observed in A− participants (rPearson = 0.76–0.95; Fig. 1 bottom row;
Supplementary Tables 2 and 3). The largest inter-method EAOA differences were observed in A− participants and at high DVR/SUVR
where longitudinal observations were sparse (Supplementary
Fig. 1). In A± convertors, EAOA accuracy ranged from 16.7% (1/6,
GBTM in BLSA) to 77% (17/22, SILA in WRAP), and the mean error
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Figure 1 Observed and modelled amyloid trajectories and EAOA. Observed amyloid PET by age (top row), modelled amyloid accumulation patterns
(middle row) and EAOA (bottom row) for each method and cohort (each column represents a cohort). APOE genotype is colour coded for plots in the
top row. Equivalent Centiloid values corresponding DVR and SUVR from each cohort are represented along the right side of the plots in the middle
and top row for reporting purposes. A+ thresholds in all cohorts were slightly above the visually apparent group of longitudinal amyloid nonaccumulators suggesting those above A+ thresholds had a high likelihood of future amyloid accumulation (see also Supplementary Fig. 8). The plots
in the middle row represent backwards prediction of the duration A+ (estimated duration A+ at ﬁrst scan using last scan for a within-person reference).
Open circles in the bottom row indicate participants who were A− at their last observation and demonstrate the instability of estimating the onset age of
A+ in cases with low amyloid levels. This suggests that interpretation of EAOA in A− cases is probably limited.
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ranged from −3.65 (GBTM in ADNI) to 1.96 years (GBTM in BLSA)
across all cohorts and methods (Supplementary Fig. 2 and
Table 4). GBTM, ODE–GP and SILA had similar EAOA accuracy and
errors in BLSA and WRAP cohorts, whereas EAOA accuracy was
lower and errors were higher for GBTM in ADNI compared to
ODE–GP and SILA.

Aim 2: EAOA, sex and APOE genotypes
APOE, sex and rate of amyloid accumulation
No differences were observed in SUVR/DVR rates versus SUVR/DVR
between males and females or between APOE-ϵ4 carriers and noncarriers (all cohorts) or between impaired versus unimpaired in
ADNI (Fig. 2 and Supplementary Figs 8–10).

Forwards and backwards predictive validity
The time for prediction evaluation ranged from 0.9 to 13.1 years. Using
holdout cross-validation in ADNI, all three methods had high balanced
accuracy (94–98%) for predicting future or antecedent A± status
(Supplementary Table 5). Sum of squared residuals were ODE–GP <
SILA < GBTM for backwards SUVR prediction, and ODE–GP < GBTM <
SILA for forwards SUVR prediction with all methods except GBTM reporting higher residual sum of squares for forwards compared to backwards SUVR prediction. Using 10-fold cross-validation in all cohorts,
ODE–GP and SILA had similar SUVR/DVR predictive performance with
balanced accuracy ranging from 94 to 99% for backwards A± prediction
and 82–96% for forwards A± prediction. Prediction error was lower for
backwards prediction compared to forwards prediction for ODE–GP
and SILA in all three cohorts. Model residuals were weakly associated
with age at reference scan (|Spearman’s rho| ≤ 0.26) and time to/from
reference scan (|Spearman’s rho| ≤ 0.28) for all methods and cohorts
(Supplementary Tables 6–9 and Supplementary Figs 3–6). ODE–GP and
SILA had weak to moderate associations between prediction residuals
and reference SUVR/DVR (|rSpearman| ≤ 0.41), whereas GBTM had a moderate association in the ADNI dataset (rSpearman = 0.45 and 0.61 for backwards and forwards prediction, respectively). EAOA was highly linearly
correlated (rPearson > 0.99) for all methods and cohorts when using
out-of-sample (10-fold or holdout cross-validation) versus in-sample
training/prediction paradigms (Supplementary Fig. 7). No convergence
issues were observed during model ﬁtting.

Effect of APOE and sex on EAOA and A+ risk
The mean (SD) estimated time between A+ thresholds across ODE–
GP and SILA methods was 0.42 (0.11) years from BLSA to WRAP and
4.53 (1.11) years from BLSA to ADNI.
At what age does A+ onset occur?
EAOA by APOE genotype is shown for each cohort in Fig. 3 for observed A+ participants. Kaplan–Meier curves by APOE-e4 status
and genotype are presented in Fig. 4. The difference in Kaplan–
Meier curves between APOE-e4− and e4+ (excluding e2e4) was statistically signiﬁcant in each dataset (ADNI P < 10−15, BLSA P = 0.003,
WRAP P = 10−11). In ADNI, the median A− survival age was 84.2
(95% conﬁdence limits: 82.7, 88.1) for e4− and 69.1 (68.2, 70.5) for
e4 + . Median survival times for e4− could not be estimated in
BLSA and WRAP because this group did not attain 50% A+ probability. Median A− survival time for e4+ was 83.0 (lower 95% conﬁdence
limit = 72.1) in BLSA and 70.7 (67.0, 73.0) in WRAP. In ADNI, all pairwise survival curve comparisons among e2e3, e2e4, e3e3, e3e4 and
e4e4 were statistically signiﬁcant (P < 0.0008) except for differences
between e2e4 and e3e4 (P = 0.33). In WRAP, e2e3 versus e3e4, e2e3 versus e4e4, e3e3 versus e3e4, and e3e3 versus e4e4 were signiﬁcant (P <
0.0002). No signiﬁcant pairwise comparisons were found in BLSA,
but the e3e3 versus e3e4 and e3e3 versus e4e4 comparisons were
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Figure 2 Amyloid accumulation rates by APOE Carriage and Sex. Comparisons of amyloid accumulation rates as a function of amyloid level between
APOE-e4 carriers and non-carriers (top row) and between males and females (bottom row) for each of the three cohorts (columns). Scatter plots show the
within-person amyloid rate as a function of their mean DVR or SUVR value. Local regression with weighted linear least squares lines show the average
relationship between the rate of amyloid change and the amyloid level for the entire sample, and for subsets of APOE-e4 carriers and non-carriers and
for females and males. Shaded regions represent the 95% conﬁdence intervals derived from 1000 bootstrapped samples. The relationship between the
amyloid accumulation rate and the level of amyloid burden was similar between APOE-e4 carriers versus non-carriers, and between males versus females across all cohorts. This suggests the rate of amyloid accumulation does not differ by APOE-e4 carriage or sex.
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near signiﬁcance (P = 0.059). In ADNI, the median A− survival time
was 83.1 (81.3, 85.4) for the e3e3, 74.2 (lower 95% conﬁdence limit
= 67.4) for e2e4, 70.5 (69.4, 71.8) for e3e4, and 64.0 (62.5, 66.4) for
e4e4. In BLSA, the median A− survival time was 83.0 (lower 95% conﬁdence limit = 72.1) for e3e4 and 63.5 (lower 95% conﬁdence limit =
57.2) for e4e4, and in WRAP, 70.7 (67.7, 73.0) and 61.7 (lower 95% conﬁdence limit = 49.1), respectively.
What is the risk of A+ conferred by APOE?
Cox proportional hazards models adjusted for sex showed e4 + was associated with a greater risk of becoming A+ in each dataset [hazard ratio (HR) (95% CI) ADNI: HR = 3.97 (3.35, 4.70), P < 10−15; BLSA: HR = 2.29
(1.35, 3.90), P = 0.002; WRAP: HR = 5.66 (3.24, 9.86), P = 10−9]. Sex and
interaction of e4+ by sex were not signiﬁcant for explaining
A+ risk. Results using APOE genotype instead of e4± for A+ risk are
shown in Supplementary Table 10. In ADNI, the e2e3 genotype was associated with a lower A+ risk compared to e3e3 [HR = 0.37 (0.22, 0.62), P
= 0.0002], whereas e2e4 was associated with higher risk [HR = 2.37
(1.40, 4.00), P = 0.0013]. In each cohort, e3e4 and e4e4 were associated
with higher A+ risk, with the point HR estimate for e4e4 being higher.
The difference in the risk conferred by e4e4 versus e3e4 was statistically signiﬁcant in ADNI only [HR = 2.25 (1.78, 2.85), P < 10−10].
Does EAOA differ between APOE groups?
AFT models adjusted for sex indicated e4+ individuals had earlier
EAOA [ADNI: β = −0.18 (−0.20, −0.16), P < 10−15; BLSA: β = −0.14 (−0.23,

−0.053), P = 0.0017; WRAP: β = −0.26 (−0.35, −0.17), P < 10−8]. Sex differences in EAOA were not signiﬁcant nor was the interaction between
APOE-e4 status and sex in any cohort. In ADNI, compared to e3e3,
the e2e3 group had a later EAOA [β = 0.12 (0.064, 0.168), P = 0.00001],
whereas e2e4 [β = −0.11 (−0.18, −0.036), P = 0.0034], e3e4 [β = −0.14
(−0.16, −0.12), P < 10−15] and e4e4 [β = −0.24 (−0.28, −0.21), P < 10−15]
groups had earlier EAOA (Supplementary Table 11). Additionally,
the e4e4 group had earlier EAOA relative to e3e4 [β = −0.10 (−0.14,
−0.067), P < 10−7]. In BLSA, compared to e3e3, the e2e4 [β = −0.21
(−0.41, −0.013), P = 0.037], e3e4 [β = −0.13 (−0.23, −0.035), P = 0.0076]
and e4e4 [β = −0.28 (−0.57, −0.011), P = 0.059] groups had earlier
EAOA. In WRAP, compared to e3e3, the e3e4 [β = −0.23 (−0.33, −0.14),
P = 0.000001] and e4e4 [β = −0.35 (−0.53, −0.17), P = 0.00015] groups
had earlier EAOA. Kaplan–Meier curves and AFT model results were
similar when using left, interval and right censoring with only observed data, but conﬁdence intervals were larger compared to primary analyses using EAOA (Supplementary material).

Aim 3: EAOA, sex, APOE and time to impairment
Participant demographics for this ADNI subset are provided in
Table 2. Interactions between sex or APOE-e4+/− with linear and
quadratic EAOA terms were not signiﬁcant (global test P = 0.44 and
P = 0.17, respectively) in Cox proportional hazard models investigating time from EAOA to impairment onset. Results for HR, median
unimpaired survival times and 10-year unimpaired survival rates
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Figure 3 EAOA by APOE genotype. Estimates are shown only for individuals whose observed A+ onset preceded their last PET visit. Data shown are the
average of the estimates computed by the SILA and ODE–GP methods. To assess whether A+ onset age differs by APOE genotype, we conducted pairwise
comparisons using AFT models, which allow inclusion of A− participants in the analyses via right censoring. The e3e4 and e4e4 groups had an earlier A+
onset compared to e3e3 in all data sets. The e3e4 A+ onset age was 13, 12 and 20% earlier in the ADNI, BLSA and WRAP, respectively, and the e4e4 A+
onset age was 21, 24 and 30% earlier. The e2e4 group had an earlier amyloid onset than the e3e3 in the ADNI (10% earlier) and BLSA (19% earlier). e2e3 had
a later amyloid onset compared to e3e3 in the ADNI only (13% later). The remaining comparisons with the e3e3 group were not statistically signiﬁcant.
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are reported as estimate (95% conﬁdence interval). In the adjusted
Cox hazard model, APOE-e4+ had a 77% greater risk of impairment
after EAOA compared to e4− [HR = 1.77 (1.33, 2.36), P < 0.0001] and
males had a 32% lower risk compared to females [HR = 0.68, (0.53,
0.88), P = 0.003]. Both EAOA and EAOA2 terms were signiﬁcant (P <
0.0001). Due to this non-linearity, we report HRs at multiple EAOA
with each HR corresponding to a decade difference in EAOA.
Impairment risk was small and not signiﬁcant for EAOA of 65 versus
55 [HR = 1.06 (0.89, 1.26)], but was signiﬁcant for EAOA of 75 versus 65
[63% greater risk; HR = 1.63 (1.33, 2.00)] and EAOA of 85 versus 75 [HR
= 2.51 (1.71, 3.68)]. Groupwise unimpaired survival curves are presented in Fig. 5A, C and D with median survival times and 10-year
unimpaired rates included in Supplementary Table 12. The median
survival time from EAOA to CDR ≥1 was 13.57 (12.98–14.08) years
with a 10-year post-EAOA survival rate of 0.744 (0.703–0.786) across

this ADNI subset. Median survival time from EAOA to impairment
was shorter for females [12.89 (11.87, 13.66) years] compared to
males [14.08 (13.57, 14.55) years], and shorter for APOE-e4+ [12.73
(11.71, 13.42) years] compared to e4− [14.42 (13.97, 15.54) years].
The 10-year post-EAOA unimpaired survival rate was lower for females [0.699 (0.644–0.755) years] compared to males [0.784 (0.736–
0.826) years], and lower for APOE-e4+ [0.691 (0.637, 0.741) years] versus e4− [0.812 (0.766, 0.857) years]. Non-linear median survival times
and 10-year unimpaired survival rates as a function of EAOA are depicted in Fig. 5E and F and Supplementary Table 13. Analyses using
APOE genotype (e3e3, e3e4, e4e4) instead of e4+ versus e4− indicated
similar results with signiﬁcant differences between e3e3 and other
genotypes, but not between e3e4 and e4e4 genotypes (Fig. 5B and
Supplemental Results). Results did not differ when accounting for
competing risk of death.
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Figure 4 A− survival as a function of age by APOE-e4 carriage and APOE genotype. Kaplan–Meier curves showing A− survival for APOE e4 carriers versus
non-carriers (top row) and for individual APOE genotypes (bottom row) across all cohorts. Individualized estimates of age A+ (average of the SILA and
ODE–GP estimates) were used for analyses. Individuals that were A− at their last available PET scan (i.e. those where Estimate Age A+ < age at last
scan) are right censored. Cox proportional hazard models indicated signiﬁcant differences between e4+ and e4− groups. The hazards for e3e4 and
e4e4 groups were higher relative to the e3e3 group in all cohorts, and additionally for the e2e4 group in ADNI. e2e3 carriers had a lower hazard in ADNI.
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Table 2 ADNI participant demographics for Aim 3 analyses
Analysis sample

Cognitively normal during follow-up

Impaired after A+ onset

P-values

595
327 (55.0%)
364 (61.2%)
566 (95.1%)
16.0 (2.8) [6–20]
68.5 (8.7) [41.1–94.9]
9.4 (4.5) [0.2–24.4]
1.03 (0.17) [0.80–1.96]
74.1 (6.9) [55.0–90.3]
78.6 (7.7) [55.7–97.4]
4.5 (3.4) [0–15.1]
77.4 (7.6) [55.6–96.5]

332 (55.8%)
175 (52.7%)
175 (52.7%)
316 (95.2%)
16.1 (2.8) [6–20]
70.8 (8.0) [49.0–94.9]
8.5 (4.5) [0.2–20.8]
0.98 (0.14) [0.80–1.59]
74.6 (6.5) [55.0–90.1]
79.3 (7.5) [59.0–97.4]
4.7 (3.3) [0–15.1]
78.2 (7.3) [59.0–96.5]

263 (44.2%)
152 (57.8%)
189 (71.9%)
250 (95.1%)
15.8 (2.7) [8–20]
65.7 (8.7) [41.1–88.6]
10.4 (4.4) [0.4–24.4]
1.09 (0.18) [0.80–1.96]
73.5 (7.3) [55.1–90.3]
77.7 (7.9) [55.7–96.0]
4.3 (3.5) [0–14.8]
76.5 (7.9) [55.6–96.0]

0.22
<0.0001
0.94
0.18
<0.0001
<0.0001
<0.0001
0.041
0.014
0.15
0.0061

Continuous variables are represented as mean (SD) [range]. Participants were included in aim three analyses if they were not impaired (i.e. CDR < 1) before the estimated age of
A+ onset. Fifteen APOE e2e4 carriers were excluded from the analyses due to small sample size and the mixture of risk and protective alleles. Group comparisons (impaired
during follow-up versus not impaired during follow-up) for continuous and categorical variables used t-tests and chi-square tests, respectively.

Discussion
We evaluated three methods to model amyloid accumulation and
estimate A+ onset age from amyloid PET data in three cohorts
with different sample characteristics, PET tracers and quantiﬁcation
methods. These novel methods were then applied to further explain
the risk and timing of amyloidosis and dementia onset associated
with age, sex and APOE genotype. Using individualized EAOA, we
found APOE genotype, but not sex, signiﬁcantly affects EAOA with
e4 homozygotes becoming positive ∼6 to 10 years earlier than e3e4
heterozygotes (all cohorts), and approximately two decades earlier
than e3 homozygotes (ADNI). Consistent with previous observations, amyloid accumulation rates are predictable and neither
APOE genotype, nor sex affected the rate of amyloid accumulation.45,46 In an ADNI subset, time from A+ onset to eventual cognitive
impairment was shorter for APOE-e4 carriers, females and people
with higher EAOA. Together, these results provide a major advance
in characterizing the temporal course of Alzheimer’s disease on an
individual basis and increase understanding of how common risk
factors affect disease proteinopathy and clinical progression.

Method comparisons and amyloid PET inference
Comparisons of the three modelling methods provide insights into
model performance, amyloid PET binding estimate interpretation
and predictability of amyloid aggregation. All methods had similar
DVR/SUVR predictive validity and produced similar EAOA, except
GBTM EAOA in ADNI, but differ in efﬁciency and autonomy. SILA
and ODE–GP are autonomous requiring ∼1 min and ∼2.5 h computational time to train and estimate model outputs, respectively,
whereas GBTM requires ∼3–4 h of human time. Because of this human resource burden and comparable or better performance of
ODE–GP and SILA methods, we forewent additional SUVR/DVR prediction evaluation for GBTM. The autonomy of ODE–GP and SILA
enables translation to additional cohorts or cohort subsets, and
adaptation to other applications such as spatiotemporal modelling.
GBTM was harder to ﬁt in the ADNI dataset, which might suggest
ODE–GP and SILA are more robust against differences in PET quantiﬁcation methods, radiotracers and/or study composition. ODE–GP
and SILA also produce non-parametric SUVR/DVR versus A+ time
curves that may better depict the observed nature of amyloid accumulation over parametric models that require assumptions of this
geometric relationship.

Amyloid accumulation patterns were similar between methods in
the A+ range with inter-method differences increasing dramatically below the A+ threshold. This observation, coupled with similarities in
DVR/SUVR rates, suggests that amyloid accumulation rates are ostensibly consistent between individuals and predictable once underlying
amyloid burden sufﬁciently exceeds amyloid PET detection limits.
This detection limit and binding estimate accuracy and variance are inﬂuenced by several factors including tracer afﬁnity and non-speciﬁc
white matter binding, acquisition length, image reconstruction, scanner resolution and image processing and quantiﬁcation methodology,
which varied across cohorts in this study.47,48 Below the A+ threshold,
DVR/SUVR interpretation gradually transitions from being due to amyloid to being due to stochastic measurement error, which is consistent
with PET detection physics,47 the concept of subthreshold amyloid49
and supports previous work proposing two thresholds50 to deﬁne three
interpretation zones: undetectable amyloid, transition and conﬁdently
A+. EAOA derived from DVR/SUVR in these zones therefore inherit a
similar interpretation, in which EAOA is interpretable in the A+ range
and becomes less interpretable as reference DVR/SUVR approaches
PET detection limits. Similarly, the accuracy and variability of reference
DVR/SUVR affect the accuracy and variability of imputed DVR/SUVR
and EAOA. Lower variability of DVR quantiﬁcation compared to SUVR,
along with previous work showing Florbetapir has higher variance compared to PiB after converting to Centiloids,51 might explain why ADNI
had a higher Centiloid threshold despite A+ thresholds delineating longitudinal amyloid non-accumulators from accumulators. For this reason and because direct comparisons of factors that affect PET
detection limits and variability were not available across cohorts, we
used previously validated methods and A+ thresholds from each cohort
that minimize PET binding estimate variance and used a study design
focused on replicating ﬁndings across cohorts and methods rather
than attempting pooled analyses across cohorts. As in our previous
work13 and a recently published similar work14 estimating individualized EAOA in people who are A+ enables estimation of A+ disease duration from a single amyloid PET scan. This ability to deﬁne disease time
from amyloid PET provides new insights into how known and unknown
factors affect dementia risk and timing in Alzheimer’s disease, which
has clinical trial implications.

APOE, EAOA and dementia timing and risk
Our results support literature showing higher APOE-e4 dosage associates with earlier amyloid and dementia onset.8,12,17–19,21–23,46
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Additionally, we observed signiﬁcant EAOA differences between
almost all compared APOE genotypes in ADNI, with similar patterns observed in BLSA and WRAP (lack of signiﬁcance potentially
due to power limitations and/or cohort makeup). Individualized
EAOA allowed us to show e4 carriage also shortens the preclinical
time from A+ onset to dementia onset (in initially unimpaired
ADNI participants, even after controlling for age and sex). These

ﬁndings suggest APOE-e4 carriers experience a double-hit wherein they accumulate amyloid earlier in life and have a shorter preclinical disease phase. Effect sizes for APOE genotype differences
in EAOA far exceeded differences in time from A+ onset to dementia suggesting that when amyloid accumulation begins is a key
factor explaining APOE associated lifetime dementia risk and
resilience.
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Figure 5 Time from amyloid onset to impairment in ADNI. (A–D) Covariate adjusted survival curves indicating the probability of remaining unimpaired
as a function of the time from A+ onset demonstrated that APOE-e4 carriage, being female and becoming A+ later in life were all associated with a shorter time from A+ onset to impairment onset (i.e. ﬁrst CDR ≥1). Dotted lines in A–C represent 95% conﬁdence intervals of the covariate adjusted survival
functions. (E and F) Median time to impairment and the 10-year unimpaired rate following A+ onset were nonlinearly associated with the EAOA such
that people who became A+ at an older age had greater risk of becoming impaired in a shorter time from A+ onset.
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Figure 6 Global CDR scores as a function of the time A+ in ADNI subsample from Aim 3 analyses. Observed longitudinal global CDR scores are plotted
as a function of estimated duration A+ for the ADNI subset used in Aim 3 analyses (top). Histograms depict the time from estimated A+ onset age (EAOA)
to global CDR = 1 colour coded by APOE genotype (middle) and by EAOA (bottom) for the subset of participants that became impaired (i.e. global CDR ≥1)
after A+ onset. Time from A+ onset to global CDR ≥1 in this ADNI subsample ranged from 0 to nearly 25 years demonstrating the heterogeneity in the
timing of dementia onset relative to A+ onset.
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Clinical implications

Strengths and limitations
This work and other recent publications,3,7,11–15,44,55 demonstrate
the robustness and use of the conceptual framework of deﬁning
Alzheimer’s disease time using amyloid PET (i.e. an ‘Amyloid
Clock’) to study disease progression. Strengths of the current study
include comparisons and consistency of results across three different methods and cohorts, prediction validation in subsets of observed A− to A+ convertors and a methodological framework for
applying individualized EAOA to characterize biomarker and dementia timing and risk in Alzheimer’s disease. Further work is
needed to better understand the impact of PET quantiﬁcation and
processing methods, radiotracers, different PET and MRI scanners,
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and cohort composition on temporal amyloid models, which affect
EAOA accuracy and harmonization. Additionally, this study used
convenience samples that were skewed towards highly educated,
non-Hispanic white people. More work is needed to collect biomarkers and validate these approaches in diverse populations.

Conclusions
This work demonstrates multiple methods for modelling amyloid
accumulation and estimating the onset age and duration of A+
from PET imaging. These novel approaches and framework can be
used to more directly investigate the timing of cognitive and pathological events in Alzheimer’s disease on an individual basis, and
understand factors that modify this timing.
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Consistent with our previous reports,12,13 this work suggests individualized EAOA and A+ duration are relevant to clinical prognosis
and treatment planning. Figures 1 and 3 demonstrate EAOA varies
widely, even within APOE genotypes, spanning ages 40 to 90+ years
across cohorts. Recruitment differences probably explain some cohort EAOA differences. Nevertheless, the broad range of EAOA
highlights the heterogeneity of when amyloid pathology begins to
accrue. These results and our previous ﬁndings13 also underscore
the need to consider the magnitude/duration of amyloid exposure
to better inform prognosis compared to binary A±. Comparatively
less heterogeneity was observed in the time from A+ onset to dementia onset (range 0–25 years post-EAOA, Fig. 6) in initially unimpaired A+ ADNI participants. Combining the amyloid chronicity
framework13 and survival analyses we showed APOE-e4 carriers, females, and people with older EAOA have shorter time from A+ onset to dementia, and that the effect of EAOA on this timing
accelerated rapidly after age 65. These methods can also establish
EAOA, sex and APOE stratiﬁed dementia risk probabilities (e.g. 1-,
5-, 10-year impairment probability) that could inform individualized patient prognoses anchored to EAOA, which might also help
identify optimal treatment windows for anti-amyloid therapies.
More work is needed to better understand additional factors that
mediate and moderate both the heterogeneity of EAOA and the timing from EAOA to impairment, and to validate risk probabilities in
larger and representative samples.
The effects of EAOA, sex and APOE on the timing between EAOA
and dementia have several potential explanations. Similar ﬁndings
regarding age, but not APOE or sex were recently reported using a
similar approach.14 EAOA shortening the preclinical timeframe
may be explained by age-associated increases in comorbidity with
other age-related diseases such as vascular disease and other neurodegenerative proteinopathies that co-occur in Alzheimer’s disease.52 APOE-e4 carriage shortening the preclinical timeframe
could represent a pleiotropic susceptibility effect of APOE on brain
health since APOE is also implicated in cerebrovascular health.53
Females having shorter preclinical disease is consistent with but
does not fully explain some epidemiologic reports of sex differences
in Alzheimer’s disease risk. These results coupled with the observations that sex did not affect EAOA or amyloid accumulation rates is
consistent with recent ﬁndings that observed no sex differences in
Alzheimer’s disease biomarker prevalence but did observe differences in MCI prevalence.54 More work is needed to understand the
basis for the observed greater vulnerability to dementia for these
risk factors. Anchoring such investigations to EAOA may facilitate
greater understanding of the relative inﬂuence of these and other
factors that are associated with increased Alzheimer’s disease risk.
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